/

IBIO

iBio, Inc.Closed

0.7818−0.12 −13.44%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.7753 −0.83%

Open

0.8977

Prev close

0.9032

Day range

0.77000.8977

52-week range

0.77003.82

Volume

1.34M1.86×

Mkt cap

50.28M

P/E ttm

—

Fwd P/E

-1.27

EPS ttm

-0.3200

Div yield

0.00%

Earnings

—

From 52w high

−79.53%

Price Chart

Yahoo Finance · delayed

IBIOOct 13, 2026O 0.9000H 0.9000L 0.7700C 0.7800−0.1200 (−13.33%)Vol 1.34M

SMA 501.2678
SMA 2001.7841

1Y change −3.70% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IBIO iBio, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −25.71%
1 month: −35.54%
3 months: −45.83%
6 months: −64.38%
Year to date: −59.59%
1 year: −3.70%

Valuation & ownership

Market cap: 50.28M
Enterprise value: −35.57M
P/E (ttm): —
Forward P/E: -1.27
PEG ratio: —
Price / book: 0.51
Price / sales (ttm): 502.75
EV / EBITDA: 1.21
EPS (ttm): -0.3200
EPS (forward): -0.6140
Beta (5y monthly): 1.26
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 64.31M
Float: 52.11M
Short % of float: 6.56%
Short ratio (days): 6.90
Held by insiders: 1.32%
Held by institutions: 55.40%
Avg volume (3m): 723.84K
50-day average: 1.28
200-day average: 1.79
52-week change: −3.70%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 19.9
vs 50-day SMA: −38.48%
vs 200-day SMA: −56.28%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 11.11%
Realised vol (20d, ann.): 79.3%
From 52-week high: −79.58%
From 52-week low: +1.30%

ANR

Analyst Consensus

9 analysts

Consensus

Strong buy

1.11 on a 1 (strong buy) – 5 (sell) scale

Mean target

5.69

+627.67% implied

Low 4.20Median 6.00High 7.00

Recommendation trend

Now9 / 0 / 0
1m ago9 / 0 / 0

DES

About iBio, Inc.

Yahoo Finance profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 23
Headquarters: San Diego, CA, United States
Website: ibioinc.com

SEAS

Seasonality · IBIO

2008–2026 · monthly returns

Strongest month Feb +61.82%Weakest month Dec −13.25%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	8.8	34.3	-32.6	-11.1	12.4	-7.9	-20.0	-9.3	-7.1	-33.7			−59.5%
2025	22.9	93.7	-31.0	-73.6	-27.4	-1.3	-10.5	20.6	1.2	92.8	-23.1	56.9	−21.2%
2024	-17.5	11.5	222.2	-57.9	39.2	-11.3	-2.8	-3.9	12.7	16.7	13.5	-16.7	+78.8%
2023	65.9	75.3	62.5	-48.1	-35.2	-12.9	-18.0	-40.0	0.0	-13.3	-37.1	-58.1	−84.4%
2022	-12.7	-33.3	34.4	-32.6	-17.2	8.3	-11.5	21.7	-39.3	-48.5	-29.7	-71.4	−96.8%
2021	52.4	10.0	-12.5	-11.0	5.8	4.1	-17.9	2.4	-16.5	-26.4	-3.8	-26.7	−47.6%
2020	12.0	775.0	-56.7	5.7	42.9	38.8	100.0	-52.9	-2.9	-14.3	-14.4	-29.5	+320.0%
2019	16.0	1.1	-1.1	-4.6	-4.8	-10.1	-5.6	-6.0	-14.3	-70.4	-31.3	127.3	−66.7%
2018	-5.6	17.6	10.0	-22.7	-17.6	-35.7	-7.8	0.0	2.4	-10.6	2.6	-3.8	−58.3%
2017	0.0	0.0	7.5	-2.3	-11.9	5.4	-20.5	-3.2	6.7	-6.3	-36.7	-5.3	−55.0%
2016	7.1	-1.7	-3.4	22.8	-2.9	5.9	-13.9	-1.6	-9.8	-5.5	-19.2	-4.8	−28.6%
2015	-30.4	108.3	-23.0	33.8	-10.7	3.3	-25.3	2.8	-6.8	-1.5	3.0	-18.8	−18.8%
2014	70.6	-8.6	1.9	-16.7	-17.8	13.5	-7.1	23.1	27.1	68.9	2.9	-34.9	+102.9%
2013	9.7	-5.9	-15.6	-20.4	2.3	-4.5	16.7	-12.2	0.0	-18.6	11.4	-12.8	−45.2%
2012	2.4	-4.7	38.3	33.9	-37.3	-19.1	51.3	-5.2	-5.5	-7.8	-23.2	-15.1	−25.3%
2011	71.2	-31.4	-17.3	-7.2	5.3	-4.7	-5.9	-20.8	-24.9	25.6	-25.9	-44.3	−73.7%
2010	-26.7	84.8	-18.0	0.0	2.0	35.3	17.4	23.5	11.0	-1.8	40.8	2.9	+251.1%
2009	100.0	-40.9	53.8	140.0	-27.1	28.6	22.2	70.9	25.5	-14.4	0.0	-10.9	+718.2%
2008									-37.5	-16.0	-52.4	-72.5	−93.1%

INSD

Insider Activity · IBIO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Mar 25, 2026	Banjak MarcOfficer	Purchase at price 1.64 - 1.76 per share.	13.9K	$23.05K
Mar 18, 2026	Brenner MartinChief Executive Officer	Purchase at price 2.02 per share.	12.3K	$24.92K
Mar 18, 2026	Duran FelipeChief Financial Officer	Purchase at price 2.02 per share.	24.8K	$50.13K
Jan 9, 2025	Arkowitz David A.Director	Purchase at price 2.72 per share.	18.4K	$50.00K
Jan 9, 2025	Clark William DDirector	Purchase at price 2.72 per share.	1.8K	$5.00K
Jan 9, 2025	Sender Gary L.Director	Purchase at price 2.72 per share.	9.2K	$25.00K
Jan 9, 2025	Brenner MartinChief Executive Officer	Purchase at price 2.72 per share.	9.2K	$25.00K
Jan 9, 2025	Duran FelipeChief Financial Officer	Purchase at price 2.72 per share.	9.2K	$25.00K
Jan 9, 2025	Banjak MarcOfficer	Purchase at price 2.72 per share.	9.2K	$25.00K
Jan 9, 2025	Parada Antonio Bernardino GuimaraesDirector	Purchase at price 2.72 per share.	183.8K	$500.00K

13F

Investors Holding IBIO

latest 13F filings of 29 followed managers

Investors holding IBIO
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$355.0K	0.00%	202.85K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

IBIO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IBIO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About iBio, Inc.

Seasonality · IBIO

Insider Activity · IBIO

Congress Trades · IBIO

Investors Holding IBIO

Investors Holding IBIO

Congress Trades · IBIO

Seasonality · IBIO

Insider Activity · IBIO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About iBio, Inc.

Financial Snapshot

Earnings & Dividends

News